本研究之目的在探討樟芝菌株CCRC93032發酵過濾液(以下簡稱樟芝發酵液) 的安全性及保健功效，為樟芝發酵液的開發與利用之基礎研究，得到如下結果： 以四氯化碳連續經口投予八週誘發慢性肝炎，樟芝發酵液由第四週開始口服投予至實驗終了，由血清生化值及肝臟膠原蛋白含量顯示樟芝發酵液(1 g/kg) 有改善四氯化碳誘發慢性肝炎的效果。另外，樟芝發酵液(2 g/kg) 也能抑制dimethylnitrosamine所引起的肝臟纖維化。經過四週的投予，樟芝發酵液(3 mg/kg)能增加盲腸的乳酸菌量。本研究也顯示樟芝發酵液(2 mg/kg) 能抑制第四型過敏反應、胃酸分泌及排尿作用。連續經口投予28天的毒性試驗顯示樟芝發酵液的安全劑量在2 g / kg以下。急性毒性試驗也發現樟芝發酵液(15 g/kg)引起嚴重下痢。 結論：樟芝發酵液有可能開發成護肝的健康食品。; The aim of the present study was to investigate the safety and potential functional application of the filtrate of fermented mycelia of Antrodia camphorata (FMAC). And this was the basic study for FMAC development and utilization. The following results were obtained. Chronic hepatitis was induced in rats by repeated oral administrations of carbon tetrachloride (CCl4) for 8 weeks. FMAC was administered orally from week 4 to the end of the experiment. FMAC (1 g/kg) ameliorated the chronic hepatitis induced by CCl4 as judged by biochemical observation and hepatic collagen contents. In addition, FMAC (2 g/kg) inhibited the liver fibrosis that was induced by dimethylnitrosamine. FMAC (3 g/kg) 4 weeks administration significantly increase the caecal lactobacilli counts. The present study also demonstrated that FMAC (2g/kg) could inhibite the type IV allergic reaction, gastric acid secretion and urine flow. The toxicity study of administration of FMAC orally daily to rats for 28 days indicated that the safe dose of FMAC was below 2 g / kg. Acute toxicity study also found that FMAC (15 g / kg) induced severe diarrhea. In conclusion, it is possible to development of FMAC for hepatoprotective health food.
